Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Knee Osteoarthritis
Interventions: Lavage with Platelet Poor Plasma (PPP); Biological
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions: Modified Atkins diet, KetoCal; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Immune-related Colitis, Colitis
Interventions: RMT, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Brainerd, Minnesota • Deer River, Minnesota • Detroit Lakes, Minnesota + 6 more

Conditions: SARS-CoV-2 Pneumonia, COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Kootenai Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Coeur d'Alene, Idaho

Conditions: Gastroenteritis Norovirus
Interventions: Placebo, Norwalk Virus; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SLC6A1
Interventions: Glycerol Phenylbutyrate; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 2 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions: Urelumab (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions: Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Intraventricular Hemorrhage, Premature Infants
Interventions: NIRS, aEEG, and CSF concentration of biomarkers; Procedure
Lead sponsor: University of Utah; Other
Eligibility: Up to 1 Year
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pitt Hopkins Syndrome
Interventions: MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 5 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stress Urinary Incontinence
Interventions: Filled bladder arm; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more

Conditions: Labor Pain, Complications; Cesarean Section, Pregnancy
Interventions: Epidural anesthesia, Combined spinal and epidural anesthesia; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasmodium Falciparum Malaria
Interventions: Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage; Drug · Device · Diagnostic Test + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: ABT-874; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Vascular Function, Racial Disparity
Interventions: Dietary Nitrates 400 mg, L-citrulline 3 g, Sildenafil 100 mg, Bosentan 125 mg; Dietary Supplement · Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Acute-On-Chronic Liver Failure
Interventions: SMT + PE-A 5%, Standard Medical Treatment; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Infection, Meningitis
Interventions: Not listed
Lead sponsor: IDbyDNA, Inc.; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Orange, California • San Diego, California • Miami, Florida

Conditions: Erosive Esophagitis
Interventions: Esophageal Barium Xray; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Ozurdex; Drug
Lead sponsor: Retina Macula Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Torrance, California

Conditions: Respiratory Diseases
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Non-menthol Cigarette Smoking, Menthol Cigarette Smoking, Synthetic Cooling Agent Cigarette Smoking, Usual Brand Cigarette Smoking, Spirometry, Questionnaire Administration, Nasal Epithelial Lining Fluid; Behavioral · Diagnostic Test · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 29 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage

Modified Atkins Diet Plus KetoCal for Adult Epilepsy

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

New Challenge Pool of Norwalk Virus Inoculum

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Impact of Contraceptives on Cervico-Vaginal Mucosa

Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

Does Bladder Instillation Reduce Time to Discharge After Sling Surgery

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

Effect of Alpelisib in Healthy Volunteers

Phase 1 BA Study, Single Center With Healthy Volunteers

Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Pediatric Infectious Disease Precision Medicine Using Sequencing Evaluation of CSF

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects

Evaluating the Impact of Synthetic Cooling Agents in Combustible Cigarettes on Smoking Perceptions and Use